High materiality8/10
CRISPR Therapeutics (CRSP) Analyst Target Update: UBS targets $80 vs price $50.23
Why it may matterVerify against the original reporting
Upside potential from UBS target.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS sets a $80 price target for CRSP; current price $50.23; analyst update.
- UBS target $80; price $50.23; CRSP
Key facts
- 01
Target: $80
- 02
Posted price: $50.23
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.